EP
MRTX

Eversept Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Eversept Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,840
Closed -$2.18M – 112
2021
Q4 		$2.18M Buy
14,840
+5,485
+59% +$852K 0.14% 77
2021
Q3 		$1.65M Buy
+9,355
New +$1.51M 0.11% 82

Other funds holding MRTX

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Eversept Partners's MRTX Position: Q1 2022 in Review

Eversept Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2022, closing a stake of 14,840 shares — an estimated $2.18M sold.

Eversept Partners first reported a position in MRTX in Q3 2021 and held it in 2 quarters. The position peaked at $2.18M in Q4 2021. 253 funds tracked by Wall St. Rank hold MRTX as of Q1 2022.

  • Eversept Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Eversept Partners sold 14,840 Mirati Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $2.18M.
  • Eversept Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Eversept Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $2.18M in Q4 2021.
  • 253 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.